Vialox vs FOXO4-DRI
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Vialox is a synthetic pentapeptide that mimics the activity of conotoxin from cone snails, acting as an antagonist of nicotinic acetylcholine receptors at the neuromuscular junction. Similar to Syn-Ake but derived from cone snail venom biochemistry, it reduces facial muscle contraction to smooth expression wrinkles.
- FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
- Half-Life
- Not applicable (topical; effect duration hours)
- Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
- Admin Route
- Topical
- Subcutaneous, Intraperitoneal (research)
- Research
- —
- —
- Typical Dose
- 0.005-0.05% in formulation
- 5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
- Frequency
- Twice daily
- 3 consecutive days per cycle
- Key Benefits
- Reduces dynamic wrinkles from repetitive facial expressions
- Reversible muscle-relaxing effect without injection
- Smooths forehead, periorbital, and perioral lines
- Complementary to collagen-stimulating peptides
- Well-studied tolerability in cosmetic concentrations
- Can be combined with Syn-Ake for dual conotoxin/viper venom effect
- Selectively clears senescent cells (senolytics)
- Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
- Demonstrated restoration of physical fitness in aged mice
- May improve healthspan and reduce age-related tissue dysfunction
- Potential for treatment of age-related pathologies driven by cellular senescence
- Does not affect healthy non-senescent cells at therapeutic doses
- Side Effects
- Generally very well-tolerated topically
- Rare contact sensitivity or mild irritation
- No clinically significant systemic neuromuscular effects at cosmetic doses
- Limited human data; largely preclinical evidence
- Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
- Weight loss observed at high doses in rodent studies
- Unknown long-term safety profile in humans
- Stacks With
- —
- —